

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 500862001810

Application Number 10/756,774

Applicant


Alan M. EZRIN, Ph.D. et al.

Filing Date January 12, 2004

Group Art Unit Not Yet Assigned

Mailing Date

February 23, 2004



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
J	1.	11/30/82	*4,361,553	Loh et al.	—	—	
J	2.	07/1984	*4,462,941	Lee et al.	7	1	
J	3.	3/26/85	*4,507,234	Kato et al.			
J	4.	1/1/91	*4,981,979	Sivam			
J	5.	5/21/91	*5,017,689	Hruby et al.			
J	6.	2/11/92	*5,087,616	Myers et al.			
J	7.	8/4/92	*5,135,736	Anderson et al.			
J	8.	8/18/92	*5,140,013	Gaudreault et al.			
J	9.	12/8/92	*5,169,933	Anderson et al.			
J	10.	4/26/94	*5,306,809	Boon et al.			
J	11.	12/27/94	*5,376,662	Ockert et al.			
J	12.	6/9/96	*5,482,930	Wei et al.			
J	13.	02/1996	*5,493,007	Burnier et al.			
J	14.	8/20/96	*5,547,667	Angelucci et al.			
J	15.	12/1996	*5,580,853	Sytkowski			
J	16.	03/18/97	*5,612,034	Pouletty, et al.			
J	17.	3/25/1997	*5,614,487	Battersby et al.			
J	18.	08/1997	*5,654,276	Barret et al.			
J	19.	9/15/98	*5,807,827	Lee et al.			
J	20.	8/31/99	*5,945,033	Yen			
J	21.	1/2000	*6,013,263	Barney et al.			
J	22.	1/2000	*6,017,536	Barney et al.			
J	23.	8/2000	*6,103,236	Suzawa et al.			
J	24.	8/2002	*6,437,092	Ezrin et al.			
J	25.		*09/623,533	Bridon, et al.	1	1	9/5/2000
J	26.		*09/623,548	Bridon, et al.	—	—	9/5/2000

EXAMINER:

DATE CONSIDERED:

12/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 500862001810	Application Number 10/756,774
	Applicant Alan M. EZRIN, Ph.D. et al.	
	Filing Date January 12, 2004	Group Art Unit Not Yet Assigned
	Mailing Date February 23, 2004	

27.		*09/657,276	Bridon, et al.	—	—	9/7/2000
28.		*09/657,295	Bridon, et al.	—	—	9/7/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
J	29.	12/1993	*9325217	PCT	—	—		
J	30.	04/1995	*9510302	PCT				
	31.	03/1996	*9606626	PCT				
	32.	6/13/91	*9108220	PCT				
	33.	1/8/98	*9800171	PCT				
	34.	5/20/99	*9924074	PCT				
	35.	05/1999	*9924075	PCT				
	36.	05/1999	*9924462	PCT				
	37.	09/1999	*9948536	PCT				
	38.	04/1994	*0602290	EPO				
	39.	3/19/98	*2,265,861	Canada				
	40.	1/19/95	*9501806	PCT				
	41.	12/21/00	*0076550 A2	PCT				
	42.	12/21/00	*0076551 A2	PCT				
	43.	8/11/93	*0554708 A1	EPO				
	44.	7/1997	*9723243	PCT				
J	45.	1/1993	*4122210	Germany	—	—		

EXAMINER:

DATE CONSIDERED:

12/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 500862001810	Application Number 10/756,774
	Applicant Alan M. EZRIN, Ph.D. et al.	
	Filing Date January 12, 2004	Group Art Unit Not Yet Assigned
	Mailing Date February 23, 2004	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)



Examiner Initials	Ref. No.	Title
J	46.	*Cancer Research, 1986, 46, 467-473.
	47.	*Bioorg. & Med. Chem. Lett., 1997, 7, (5), 617-622.
	48.	*J. Med. Chem., 1998, 41, 2701-2708.
	49.	*Chem. Pharm. Bull., 1997, 45, (2), 399-401.
	50.	*J. Pharm. Sci., 1998, 87 (3), 338-346.
	51.	*Anti-cancer Drugs, 1999, 10, 785-790.
	52.	*Clinical Cancer Research, 1999, 5, 753-759.
	53.	*European J. Cancer, 1995, 31A (2), 283-284.
	54.	*J. Pharm. & Experimental Therapeutics, 1981, 219 (2), 389-393.
	55.	*Ann. NY Acad. Sciences, 1971, 186, 284-286.
	56.	*International J. Pharmaceutics, 1991, 67, 177-184.
	57.	*International J. Pharmaceutics, 1993, 89, 91-102.
	58.	*Proc. Natl. Acad. Sci., 1996, 93 (5), 2186-2191.
	59.	*Anti-Cancer Drugs, 1997, 8, 677- 685.
	60.	*Anti-Cancer Research, 1994, 14, 1943-1950.
	61.	*Neoplasma, 1988, 35, (3), 329-342.
	62.	*Neoplasma, 1988, 35, (3), 343-349.
	63.	*Anti-Cancer Drugs, 1997, 8, 835-844.
	64.	*J. Surgical Research, 1991, 50, 156-162.
	65.	*Anti-Cancer Drugs, 1999, 10, 405-411.
	66.	*European J. Nucl. Med., 1995, 22 (9), 989-996.
	67.	*Biol. Pharm. Bull., 1998, 21, (1), 56-61.
	68.	*Br. J. Cancer, 1993, 67, 274-278.

EXAMINER:

DATE CONSIDERED:

12 / 05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 500862001810	Application Number 10/756,774
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Alan M. EZRIN, Ph.D. et al.	
		Filing Date January 12, 2004	Group Art Unit Not Yet Assigned
		Mailing Date February 23, 2004	
<p style="text-align: center;">OTHER DOCUMENTS <i>(including author, title, Date, Pertinent Pages, Etc.)</i></p>			
	69.	*Nucl. Med. Biol., 1992, 19 (6), 685-695.	
	70.	*Drug Delivery, 1999, 6, 89-95.	
	71.	*Cancer Research, 1993, 53, 4238-4242.	
	72.	*Science, 1993, 261, 212-215.	
	73.	*Biotech Report, 1994/1995, 106-107.	
	74.	*Proceedings of the 8th American Peptide Symposium, 1983, 409-412.	
	75.	*Int. J. Biochem. Cell. Biol. 1998, 30, 1281-1284.	
	76.	*Endocrinology, 1982, 110 (3), 1049-1051.	
	77.	*J. Biol. Chem. 1995, 270 (43), 25344-25347.	
	78.	*J. Dev. Physiol., 1989, 12, 55-62.	
	79.	*Biopolymers (Peptide Science), 1998, 47, 451-463.	
	80.	*Ann. Rev. Neurosci, 1984, 7, 223-255.	
	81.	*Chem. Pharm. Bull. 1979, 27, (8), 1942-1944.	
	82.	*Proc. Natl. Acad. Sci. 1986, 83, 265-269.	
	83.	*TINS, 1993, 16, 403-409.	
	84.	*Methodological Surveys in Biochemistry and Analysis, 15, 1985.	
	85.	*Metodol. Surv. Biochem Anal., vol. 15, 1985, pp. 109-114.	
	86.	*Indian Journal of Biochemistry & Biophysics, 30, 4/93.	
	87.	*Indian J. Biochem. Biophys., vol. 30, no. 2, 1993, pp. 117-122.	
	88.	*J. of Histochemistry and Cytochemistry, 32, (9), 1984.	
	89.	*J. Histochem. Cytochem, vol. 32, no. 9, 1984, pp. 945-957.	
	90.	*Cell Tissue Res. 215 (3), 1981.	
	91.	*Cell Tissue Res., vol. 215, no. 3, 1981, pp. 577-589.	
	92.	*Int. Congr. Ser. Excerpta Medica, vol. 471, 1978, pp. 177-186.	
93.	*Febs Letters, vol. 70, no. 1, 1976.		
94.	*Analytical Biochemistry, vol. 215, no. 1, 1993, pp. 1-8		
EXAMINER: 		DATE CONSIDERED: 12/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 500862001810	Application Number 10/756,774
	Applicant Alan M. EZRIN, Ph.D. et al.	
	Filing Date January 12, 2004	Group Art Unit Not Yet Assigned
	Mailing Date February 23, 2004	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

- | | |
|------|---|
| 95. | *Filho, Pharm Sci. 2, 1996, pp. 199-201. |
| 96. | *Correa, Pharm Sci. 3, 1997, pp. 67-71. |
| 97. | *Peptide Research 8 (3) 1995, pp. 124-137. |
| 98. | *The J. of Pharm & Experimental Therapeutics, 280, 1997, pp. 1210-1214. |
| 99. | *Blood Cells, Molecules and Diseases 23 (3), 1997, pp. 58-68. |
| 100. | *Abstract JP 59138958, 1984, Mitsubishi Chemical Industries Co. JP. |
| 101. | *Database Biosis, Accession No. XP-002172298 |
| 102. | *Patent Abstracts of Japan No. 62138430 |
| 103. | *Biochimica et Biophysica Acta, 1991, 1118, 83-90 |
| 104. | *J. Med. Chem., 2000, 43, 1253-1256 |
| 105. | *J. Med. Chem., 1998, 41, 853-863 |
| 106. | *Allergie et Immunologie, 1996, 28, 186-191 |
| 107. | *European J. Pharmaceutical Sciences, 1996, 4, 307-319 |

EXAMINER:

DATE CONSIDERED:

12/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.